# Alloy Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alloy-therapeutics

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.alloytx.com
- Total disclosed funding: $147M
- Latest round: Series E (Mar 31, 2026)
- Investors on record: 11

## About

Alloy Therapeutics, Inc., based in Waltham, US, specializes in innovative antibody discovery and development solutions aimed at accelerating therapeutic drug development for various diseases. Founded in 2017 in Waltham, Massachusetts, Alloy Therapeutics, Inc. is engaged in antibody discovery and development services.  Errik Anderson serves as the CEO, continuing the company’s commitment to advancing antibody-based therapeutics.Alloy Therapeutics specializes in antibody discovery and development services, offering a comprehensive suite of integrated solutions designed to expedite the therapeutic drug discovery process. Their core product offerings include in vivo discovery platforms and services for monoclonal and bispecific antibodies, alongside specialized capabilities in TCRm antibodies that target intracellular peptides presented on MHC complexes. The company’s Anticlastic™ antisense format is engineered for enhanced potency and safety, addressing key challenges in the development of antisense oligonucleotide (ASO) drug candidates. Their platforms serve a diverse client base that includes biotechnology and pharmaceutical companies across North America, Europe, and Asia, focusing on therapeutic applications in oncology and infectious diseases. By providing access to advanced technologies, Alloy Therapeutics aims to enhance the efficiency of drug development and improve patient outcomes.Alloy Therapeutics operates a B2B model, engaging with partners and clients through collaborative agreements and service contracts. Transactions typically involve comprehensive service packages that incorporate various stages of drug discovery, from initial antibody discovery to lead optimization. Pricing structures are situated around partnerships that leverage their proprietary technology platforms, including their flagship offerings such as Keyway™ TCRm discovery and Anticlastic™ antisense molecules. The company emphasizes collaborative innovation, allowing clients to utilize their vast expertise and advanced technologies in drug development projects. Revenue generation occurs through these strategic partnerships, enhancing the overall therapeutic index and delivery mechanisms for their clients' drug candidates. In April 2026, Alloy Therapeutics, Inc. raised USD 40 million in series E funding from Echo Capital, JIC Venture Growth Investments, Thiel Capital, Presight Capital, Mubadala Capital, 8VC, Alexandria Venture Investments, Gaingels, Ulysses Holdings, and Founders Fund. The company plans to use the April 2026 funding to expand its AI-driven drug discovery platform, strengthen preclinical and clinical development services, and invest in data and machine learning infrastructure across its biotech workflows.

## Funding rounds

- Series E, Mar 31, 2026, $30M — Alexandria Venture Investments, Founders Fund, 8VC, Gaingels, Mubadala Capital, Ulysses Holdings, Thiel Capital, Presight Capital, JIC Venture Growth Investments, Echo Capital
- Series D, Sep 16, 2022, $42M — Founders Fund, 8VC, Gaingels, Mubadala Capital, Thiel Capital, Presight Capital
- Series C, Mar 19, 2021, $75M — Alexandria Venture Investments, Founders Fund, 8VC, Gaingels, Mubadala Capital, Ulysses Holdings, Presight Capital, Luma Bio-IT Management

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series C, Series E
- Founders Fund (https://capitalatlas.ai/funds/founders-fund) — Series C, Series D, Series E
- 8VC (https://capitalatlas.ai/funds/8vc) — Series C, Series D, Series E
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Series C, Series D, Series E
- Mubadala Capital (https://capitalatlas.ai/funds/mubadala-capital) — Series C, Series D, Series E
- Ulysses Holdings (https://capitalatlas.ai/funds/ulysses-holdings) — Series C, Series E
- Presight Capital — Series C, Series D, Series E
- Luma Bio-IT Management (https://capitalatlas.ai/funds/luma-bio-it-management) — Series C
- Thiel Capital — Series D, Series E
- JIC Venture Growth Investments (https://capitalatlas.ai/funds/jic-venture-growth-investments) — Series E
- Echo Capital — Series E